
CLAIMS

1. Use of a compound binding to the sigma-receptor in the manufacture of a medicament for the treatment or prevention of osteoarthritis, and/or for the treatment or prevention of pain due to osteoarthritis.

2. Use of the compound according to claim 1, wherein the use is for the prevention of pain due to osteoarthritis, preferably for the treatment of pain due to osteoarthritis, preferably wherein the treatment or the pain is selected from acute and/or chronic pain due to osteoarthritis, especially neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

3. Use of the compound according to claim 1 or 2, wherein the compound is selected from a sigma receptor antagonist, a neutral antagonist, an inverse agonist or a partial antagonist, and/or wherein the compound binds to the sigma-1 receptor subtype.

4. Use of the compound according to claim 1 or 3, wherein the compound is a compound according to formula I:



(I)

wherein

R_1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR_8, -$C(O)OR_8$, -$C(O)NR_8R_9$, -$CH=NR_8$, -CN, -OR_8, -$OC(O)R_8$, -$S(O)t\text{-}R_8$, -NR_8R_9, -$NR_8C(O)R_9$, -NO_2, -$N=CR_8R_9$, and halogen;

R_2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR_8, -$C(O)OR_8$, -$C(O)NR_8R_9$, -$CH=NR_8$, -CN, -OR_8, -$OC(O)R_8$, -$S(O)t\text{-}R_8$, -NR_8R_9, -$NR_8C(O)R_9$, -NO_2, -$N=CR_8R_9$, and halogen;

R_3 and **R_4** are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR_8, -$C(O)OR_8$, -$C(O)NR_8R_9$, -$CH=NR_8$, -CN, -OR_8, -$OC(O)R_8$, -$S(O)t\text{-}R_8$, -NR_8R_9, -$NR_8C(O)R_9$, -NO_2, -$N=CR_8R_9$, and halogen, or together they form an optionally substituted fused ring system;

R_5 and **R_6** are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR_8, -$C(O)OR_8$, -$C(O)NR_8R_9$, -$CH=NR_8$, -CN, -OR_8, -$OC(O)R_8$, -$S(O)t\text{-}R_8$, -NR_8R_9, -$NR_8C(O)R_9$, -NO_2, -$N=CR_8R_9$, and halogen, or together form, with the nitrogen atom to which

they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group;

n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;

t is 1,2 or 3;

R_8 and **R_9** are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen;

or a pharmaceutically acceptable salt, isomer or solvate thereof.

5. Use of the compound according to claim 4, wherein the compound is characterized in that R_1 is hydrogen.


6. Use of the compound according to claim 4 or 5, wherein the compound is characterized in that R_2 is H or alkyl, preferably methyl or H; and/or
wherein the compound is characterized in that R_3 and R_4 together with the phenyl forms a naphthyl group.

7. Use of the compound according to claims 4 to 6, wherein the compound is characterized in that n is selected from 2, 3, 4, more preferably n is 2; and/or
wherein the compound is characterized in that R_5 and R_6, together, form a morpholine-4-yl group.

8. Use of the compound according to claims 1 to 7, wherein the compound is selected from 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or its pharmaceutically acceptable salts or solvates and 4-{2-[5-Methyl-1-

(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride or solvates thereof.

9. Use of the compound according to claim 1 or 3, wherein the compound is a compound according to formula II:



(II)

wherein

R'1 represents substituted or unsubstituted aromatic or non-aromatic heterocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted cycloalkyl;

R'2 and **R'3**, identical or different, represent a hydrogen atom; F; Cl; Br; I; CF_3; OH; SH; NH_2; CN; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C=O)-R'7 group; a (C=O)-O-R'8 group; a $S(O)_t$-R'9 group; or a (C=O)-NR'10R'11 group;

R'4 and **R'5**, identical or different, represent a hydrogen atom; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic

heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C=O)-R'^{7} group; a (C=O)-O-R'^{8} group; a S(O)$_{t'}$-R'^{9} group; or a (C=O)-NR'^{10}R'^{11} group;

or

together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group;

X represents an oxygen atom or a CH-R'^{12} group wherein R'^{12} is selected from H, CH_3, SH, OH, NH_2, CF_3, Cl, F, Br, I, and CN;

m' is selected from 1, 2, 3 and 4;

n' is selected from 1, 2, 3 and 4;

t' is selected from 1, 2 and 3;

R'^{7}, **R'^{8}**, **R'^{9}**, **R'^{10}** and **R'^{11}**, identical or different, represent a hydrogen atom; substituted or unsubstituted C_{1-6} alkyl; substituted or unsubstituted C_{1-6} alkenyl; substituted or unsubstituted C_{1-6} alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl;

or a pharmaceutically acceptable salt, isomer or solvate thereof.

10. Use of the compound according to claim 9 wherein the compound is characterized in that R'^{1} is selected from a 5-to 10 membered substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group which preferably contains N, O or S as ring member; a 5-to 10 membered substituted or unsubstituted aryl group; and a 5-to 10 membered substituted or unsubstituted cycloalkyl group, more preferably

R'^1 is selected from substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphtyl, substituted or unsubstituted thiophene, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzofuran, substituted or unsubstituted pyridine and substituted or unsubstituted quinoline.

11. Use of the compound according to claim 9 or 10 wherein the compound is characterized in that R'^2 and R'^3 are independently selected from H and substituted or unsubstituted C_{1-6} alkyl group, preferably methyl, more particular R'^2 is methyl and R'^3 is H, or R'^2 and R'^3 are simultaneously H, or simultaneously methyl.

12. Use of the compound according to claims 9 to 11 wherein the compound is characterized in that R'^4 and R'^5 form together with the nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, more preferably, R'^4 and R'^5 form together a morpholine-4-yl group, a piperidine-4-yl group, pyrrolidine-4-yl group or a piperazine-4-yl group.

13. Use of the compound according to claims 9 to 12 wherein the compound is characterized in that m' and n' are independently 1 and 2; and/or wherein the compound is characterized in that X preferably represents an oxygen atom or a $-CH_2-$ group.

14. Use of the compound according to claims 9 to 13 wherein the compound is selected from 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone or its pharmaceutically acceptable salts or solvates, and 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl) methoxy)ethyl)piperazin-1-yl)ethanone hydrochloride or solvates thereof.

15. Use of the compound according to claims 1 to 3 wherein the compound is selected from 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone or its pharmaceutically acceptable salts or solvates, and 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl) methoxy)ethyl)piperazin-1-yl)ethanone

hydrochloride or solvates thereof, or wherein the compound is selected from 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or its pharmaceutically acceptable salts or solvates and 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride or solvates thereof.